Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere

Woodward DF, Wang JW, Stamer WD, Lütjen-Drecoll E, Krauss AHP, Toris CB (2019)

Publication Type: Journal article

Publication year: 2019

Journal

Journal of Ocular Pharmacology and Therapeutics Mary Ann Liebert

DOI: 10.1089/jop.2019.0041

Abstract

For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit.

Authors with CRIS profile

Elke Lütjen-Drecoll Lehrstuhl für Funktionelle und Klinische Anatomie

Involved external institutions

Imperial College London / The Imperial College of Science, Technology and Medicine GB United Kingdom (GB) University of Nebraska Medical Center (UNMC) US United States (USA) (US) Duke University US United States (USA) (US)

How to cite

APA:

Woodward, D.F., Wang, J.W., Stamer, W.D., Lütjen-Drecoll, E., Krauss, A.H.-P., & Toris, C.B. (2019). Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere. Journal of Ocular Pharmacology and Therapeutics. https://dx.doi.org/10.1089/jop.2019.0041

MLA:

Woodward, David F., et al. "Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere." Journal of Ocular Pharmacology and Therapeutics (2019).

BibTeX: Download